Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Clin Transl Oncol. 2017 Mar;19(3):273-278. doi: 10.1007/s12094-016-1547-4. Epub 2016 Sep 21.


Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response.

Keywords: Biomarkers; Glioblastoma; PARP inhibitor; PTEN.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / therapy
  • Chemoradiotherapy*
  • Glioblastoma / genetics*
  • Glioblastoma / therapy
  • Humans
  • Mutation / genetics*
  • PTEN Phosphohydrolase / genetics*
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Prognosis


  • Biomarkers, Tumor
  • Poly(ADP-ribose) Polymerase Inhibitors
  • PTEN Phosphohydrolase
  • PTEN protein, human